Article
Driving Precision Medicine With Exceptional Responders
The NCI wants to encourage clinical trial investigators to review data from their completed clinical trials and treating oncologists to look back in their patient records to identify potential cases of exceptional responses and submit them for consideration in the initiative.
As part of its Exceptional Responders Initiative, the National Cancer Institute (NCI) continues to reach out to the oncology community.
The initiative is collecting cases in which patients with any cancer had dramatic and long-lasting responses to standard and experimental treatments that were not seen in similar patients who received the same treatment.
By studying tissue, clinical, and genomic data from these patients, NCI scientists hope to learn whether such exceptional responses can provide broader insights into the genetic mechanisms that underlie such responses and suggest therapeutic options that weren’t previously apparent, explained Barbara Conley, MD, of NCI’s Division of Cancer Treatment and Diagnosis.
Link to the complete article on NCI's website:
First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1
